Powered by Xconomy, November 2019’s What’s Next in Neuroscience Therapies event brought together scientists, entrepreneurs and biotech executives at the Hyatt Regency San Francisco to discuss their work developing next-generation neuroscience therapies and technologies in areas such as spinal-cord injuries, precision mental health, dementia and Alzheimer’s disease.
Allergan will pay $750 million to settle a class action lawsuit from a group of direct purchasers of the Alzheimer’s disease therapy Namenda in a resolution to the litigation that was set to face trial.
Incidence of Alzheimer’s disease is projected to double in the next 40 years unless a cure or preventive measures are found.
Researchers in Japan and Australia say they have made important progress in developing a blood test that could in future help doctors detect who might go on to get Alzheimer’s disease.
Eisai Inc. and Boston University School of Medicine have formed a research collaboration to study the effects of Alzheimer’s disease-associated genetic variants on the behavior of brain cells, called microglia.
Billionaire Microsoft co-founder Bill Gates is to invest $50 million in the Dementia Discovery Fund, a venture capital fund that brings together industry and government to seek treatments for the brain-wasting disease.
(Reuters Health) – Seniors with hearing loss who use hearing aids may experience cognitive decline at a rate more like their peers without hearing trouble, according to a French study that followed thousands of seniors for 25 years. Past research has shown a link between hearing loss and steeper cognitive decline in old age, but […]
One in three people born in Britain in 2015 will develop dementia, according to an analysis commissioned by the charity campaign group Alzheimer’s Research UK. The study, conducted by the Office of Health Economics, shows “a looming national health crisis as the UK population ages”, the charity said, and underlines the need for global efforts […]
Allergan Plc said on Thursday the U.S. Food and Drug Administration approved its new antipsychotic drug to treat bipolar disorder and schizophrenia. The drug, Vraylar, carries a boxed warning on increased risk of death associated with its use in older people with dementia-related psychosis, the FDA said on its website. Vraylar was approved after showing […]
Intra-Cellular Therapies Inc said a higher dose of its lead drug was found to be effective in reducing the severity of schizophrenia symptoms in a late-stage study, sending its shares up more than 50 percent in premarket trading. Patients treated with 60 mg of the drug, ITI-007, showed improvement over placebo. The 40 mg dosage, […]